Indaptus Therapeutics, Inc. (INDP) Scorecard
- 2026-Q2: Total return Win; Revenue growth No data; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth No data; EPS growth Win.
18/50
1.8 / 5 stars
All 50 Win/Lose results and 70 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 2 wins, 6 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/2 |
WinINDP / S&P 64.84% / 15.20% |
No dataINDP / S&P / 15.00% |
LoseINDP / S&P -83.20% / 50.40% |
| 2026-Q10/2 |
LoseINDP / S&P -37.46% / -4.33% |
No dataINDP / S&P / 11.30% |
LoseINDP / S&P -63.10% / 27.70% |
| 2025-Q40/2 |
LoseINDP / S&P 1.39% / 2.65% |
No dataINDP / S&P / 9.00% |
LoseINDP / S&P -26.60% / 13.40% |
| 2025-Q31/2 |
LoseINDP / S&P -72.74% / 8.12% |
No dataINDP / S&P / 4.61% |
WinINDP / S&P 36.72% / 13.45% |
| 2025-Q21/2 |
LoseINDP / S&P -31.62% / 10.94% |
No dataINDP / S&P / 4.83% |
WinINDP / S&P 158.90% / 10.63% |
| 2025-Q11/2 |
LoseINDP / S&P -34.68% / -4.27% |
No dataINDP / S&P / 4.98% |
WinINDP / S&P 2244.94% / 10.57% |
| 2024-Q41/2 |
LoseINDP / S&P -32.10% / 2.41% |
No dataINDP / S&P / 5.25% |
WinINDP / S&P 1697.83% / 6.15% |
| 2024-Q31/2 |
LoseINDP / S&P -41.51% / 5.89% |
No dataINDP / S&P / 5.89% |
WinINDP / S&P 1177.35% / 6.11% |
| 2024-Q21/2 |
LoseINDP / S&P -5.36% / 4.28% |
No dataINDP / S&P / 5.38% |
WinINDP / S&P 726.70% / 5.12% |
| 2024-Q11/2 |
WinINDP / S&P 27.27% / 10.56% |
No dataINDP / S&P / 5.71% |
LoseINDP / S&P -2.73% / 5.59% |
| 2023-Q40/1 |
LoseINDP / S&P -36.12% / 11.69% |
No dataINDP / S&P / 6.81% |
No dataINDP / S&P / 7.78% |
| 2023-Q31/1 |
WinINDP / S&P 44.24% / -3.27% |
No dataINDP / S&P / 7.52% |
No dataINDP / S&P / -5.03% |
| 2023-Q20/1 |
LoseINDP / S&P 3.24% / 8.74% |
No dataINDP / S&P / 9.50% |
No dataINDP / S&P / -8.57% |
| 2023-Q11/1 |
WinINDP / S&P 27.59% / 7.50% |
No dataINDP / S&P / 10.77% |
No dataINDP / S&P / -15.69% |
| 2022-Q40/1 |
LoseINDP / S&P -32.87% / 7.56% |
No dataINDP / S&P / 11.88% |
No dataINDP / S&P / -17.99% |
| 2022-Q30/1 |
LoseINDP / S&P -17.24% / -4.88% |
No dataINDP / S&P / 13.47% |
No dataINDP / S&P / -1.41% |
| 2022-Q20/1 |
LoseINDP / S&P -34.75% / -16.10% |
No dataINDP / S&P / 13.71% |
No dataINDP / S&P / 11.04% |
| 2022-Q10/1 |
LoseINDP / S&P -29.82% / -4.60% |
No dataINDP / S&P / 15.97% |
No dataINDP / S&P / 42.23% |
| 2021-Q40/1 |
LoseINDP / S&P -27.20% / 11.03% |
No dataINDP / S&P / 15.00% |
No dataINDP / S&P / 96.40% |
| 2021-Q30/1 |
LoseINDP / S&P -43.59% / 0.58% |
No dataINDP / S&P / 10.77% |
No dataINDP / S&P / 69.42% |
| 2021-Q20/1 |
LoseINDP / S&P -20.59% / 8.55% |
No dataINDP / S&P / 6.58% |
No dataINDP / S&P / 51.81% |
| 2021-Q11/1 |
WinINDP / S&P 26.67% / 6.17% |
No dataINDP / S&P / -1.06% |
No dataINDP / S&P / 7.39% |
| 2020-Q40/1 |
LoseINDP / S&P -31.55% / 12.15% |
No dataINDP / S&P / -3.72% |
No dataINDP / S&P / -33.42% |
| 2020-Q30/1 |
LoseINDP / S&P -10.95% / 8.93% |
No dataINDP / S&P / -2.04% |
No dataINDP / S&P / -27.10% |
| 2020-Q21/1 |
WinINDP / S&P 43.65% / 20.54% |
No dataINDP / S&P / -0.46% |
No dataINDP / S&P / -27.11% |
| 2020-Q10/1 |
LoseINDP / S&P -60.60% / -19.60% |
No dataINDP / S&P / 3.47% |
No dataINDP / S&P / -14.75% |
| 2019-Q40/1 |
LoseINDP / S&P -31.41% / 9.07% |
No dataINDP / S&P / 5.36% |
No dataINDP / S&P / 2.99% |
| 2019-Q30/1 |
LoseINDP / S&P -83.20% / 1.70% |
No dataINDP / S&P / 5.02% |
No dataINDP / S&P / 0.21% |
| 2019-Q20/1 |
LoseINDP / S&P -40.79% / 4.30% |
No dataINDP / S&P / 6.64% |
No dataINDP / S&P / 8.65% |
| 2019-Q10/1 |
LoseINDP / S&P -2.79% / 13.65% |
No dataINDP / S&P / 8.12% |
No dataINDP / S&P / 14.29% |
| 2018-Q41/1 |
WinINDP / S&P 33.45% / -13.52% |
No dataINDP / S&P / 9.05% |
No dataINDP / S&P / 18.23% |
| 2018-Q31/1 |
WinINDP / S&P 28.41% / 7.71% |
No dataINDP / S&P / 10.21% |
No dataINDP / S&P / 19.06% |
| 2018-Q20/1 |
LoseINDP / S&P -30.43% / 3.43% |
No dataINDP / S&P / 9.03% |
No dataINDP / S&P / 14.46% |
| 2018-Q11/1 |
WinINDP / S&P 22.82% / -0.76% |
No dataINDP / S&P / 7.68% |
No dataINDP / S&P / 12.46% |
| 2017-Q40/1 |
LoseINDP / S&P -42.46% / 6.64% |
No dataINDP / S&P / 7.03% |
No dataINDP / S&P / 13.82% |
| 2017-Q31/1 |
WinINDP / S&P 57.02% / 4.48% |
No dataINDP / S&P / 5.68% |
No dataINDP / S&P / 17.57% |
| 2017-Q21/1 |
WinINDP / S&P 11.48% / 3.09% |
No dataINDP / S&P / 4.83% |
No dataINDP / S&P / 17.74% |
| 2017-Q10/1 |
LoseINDP / S&P -10.30% / 6.07% |
No dataINDP / S&P / 3.67% |
No dataINDP / S&P / 13.32% |
| 2016-Q40/1 |
LoseINDP / S&P -3.06% / 3.82% |
No dataINDP / S&P / 2.09% |
No dataINDP / S&P / 7.05% |
| 2016-Q31/1 |
WinINDP / S&P 27.85% / 3.85% |
No dataINDP / S&P / 0.20% |
No dataINDP / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | INDP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -82.15% | 20.78% |
| Annualized return | -82.15% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | INDP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.61% | 83.14% |
| Annualized return | -66.94% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | INDP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.99% | 319.30% |
| Annualized return | -60.90% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |